Literature DB >> 2138452

Lipoprotein(a), fibrin binding, and plasminogen activation.

J Loscalzo1, M Weinfeld, G M Fless, A M Scanu.   

Abstract

Lipoprotein(a) (Lp[a]) is a complex plasma lipoprotein in which apolipoprotein (apo) B-100 is covalently linked by a disulfide bridge to a unique apolipoprotein, apo(a). The cDNA of apo(a) has recently been isolated and sequenced, and a remarkable homology to human plasminogen has been noted. In this report, we demonstrate that, like plasminogen, Lp(a) binds to fibrin. In addition, Lp(a) competes with plasminogen and tissue-type plasminogen activator for fibrin binding. As a functional consequence of these binding properties, we show that Lp(a) attenuates the fibrin-dependent enhancement of tissue-type plasminogen activator activity against the native substrate, and does so as an uncompetitive inhibitor (Ki = 15 nM). Finally, we show that in a plasma milieu, Lp(a) attenuates clot lysis induced by tissue-type plasminogen activator. None of these effects was noted with low density lipoprotein free of apo(a). These data suggest that Lp(a) influences the fibrinolytic system and probably does so by virtue of the fibrin binding properties conferred by the kringle repeats of apo(a).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138452     DOI: 10.1161/01.atv.10.2.240

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  35 in total

1.  Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin.

Authors:  L Slunga; O Johnson; G H Dahlén
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Acute Pulmonary Embolism in a Healthy Male With Elevated Lipoprotein(a).

Authors:  Subhankar Samal; Namrata Singhania; Saurabh Bansal; Anil Singh
Journal:  Cureus       Date:  2020-05-07

3.  Lipoprotein (a): a possible link between lipoprotein metabolism and thrombosis.

Authors:  A Rees
Journal:  Br Heart J       Date:  1991-01

Review 4.  Lp(a): Addressing a Target for Cardiovascular Disease Prevention.

Authors:  Nestor Vasquez; Parag H Joshi
Journal:  Curr Cardiol Rep       Date:  2019-07-31       Impact factor: 2.931

5.  Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.

Authors:  Michael B Boffa; Tanya T Marar; Calvin Yeang; Nicholas J Viney; Shuting Xia; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2019-09-24       Impact factor: 5.922

Review 6.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Authors:  Nosratola D Vaziri
Journal:  Kidney Int       Date:  2016-04-26       Impact factor: 10.612

Review 7.  Lipoprotein (a). Heterogeneity and biological relevance.

Authors:  A M Scanu; G M Fless
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

8.  Abnormal lipoprotein(a) levels predict coronary artery calcification in Southeast Asians but not in Caucasians: use of noninvasive imaging for evaluation of an emerging risk factor.

Authors:  Abhinav Sharma; Manoefris Kasim; Parag H Joshi; Zhen Qian; Eric Krivitsky; Kamran Akram; Sarah Rinehart; Gustavo Vazquez; Joseph Miller; Mohammad Saifur Rohman; Szilard Voros
Journal:  J Cardiovasc Transl Res       Date:  2011-04-12       Impact factor: 4.132

Review 9.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

10.  Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.

Authors:  J M Edelberg; S V Pizzo
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.